Heterocyclic Amides as Kinase Inhibitors (2015)
GlaxoSmithKline Intellectual Property Development Limited
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application PCT/IB2014/059004, filed Feb 14, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,556,152 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence UsedRemaining | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence | ||
| US 9,624,202 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence | ||
| US 10,292,987 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence | ||
| US 10,933,070 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence | ||
| US 10,940,154 | Heterocyclic Amides as Kinase Inhibitors In force · High confidence | GlaxoSmithKline Intellectual Property Development Limited | In force | High confidence | ||
| Application 15/835,747 | Heterocyclic Amides as Kinase Inhibitors Abandoned Abandoned Mar 13, 2019 | GlaxoSmithKline Intellectual Property Development Limited | Abandoned | Abandoned Mar 13, 2019 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by GlaxoSmithKline Intellectual Property Development Limited.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.